TIM3, like both PD1 and LAG3, is found on CD8 T cells, and increased expression has been implicated in immune evasion in various tumor types, including gastroesophageal cancer.[29-31] Currently, TIM3 inhibitors are being evaluated in early phase studies for various advanced solid tumors, which include esophageal cancer; however, there are no current studies specifically addressing esophageal or gastric malignancies, and preliminary results have not yet been reported. Here, HAVCR2 is linked to neoplasm.